Test dell'uso di farmaci sperimentali atezolizumab e/o bevacizumab con o senza chemioterapia standard nel trattamento di seconda linea dei tumori della testa e del collo in stadio avanzato
Uno studio di fase II/III di chemioterapia + cetuximab vs chemioterapia + bevacizumab vs atezolizumab + bevacizumab dopo la progressione dell'inibizione del checkpoint immunitario nei tumori della testa e del collo ricorrenti/metastatici
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Cisplatin and carboplatin are in a class of chemotherapy medications known as platinum-containing compounds. They work by killing, stopping, or slowing the growth of cancer cells. Docetaxel is in a class of chemotherapy medications called taxanes. It stops cancer cells from growing and dividing and may kill them. The addition of bevacizumab to standard chemotherapy or combination therapy with bevacizumab and atezolizumab may be better than standard chemotherapy plus cetuximab in treating patients with recurrent/metastatic head and neck cancers.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
- Carcinoma a cellule squamose della testa e del collo ricorrente
- Carcinoma ipofaringeo a cellule squamose ricorrente
- Carcinoma laringeo a cellule squamose ricorrente
- Carcinoma a cellule squamose metastatico della testa e del collo
- Carcinoma orofaringeo mediato da HPV in stadio IV (p16-positivo) AJCC v8
- Carcinoma ipofaringeo stadio IV AJCC v8
- Cancro della laringe in stadio IV AJCC v8
- Stadio IV Cancro del labbro e della cavità orale AJCC v8
- Carcinoma orofaringeo stadio IV (p16-negativo) AJCC v8
- Carcinoma a cellule squamose ipofaringeo metastatico
- Carcinoma laringeo a cellule squamose metastatico
- Carcinoma metastatico del labbro e del cavo orale
- Carcinoma a cellule squamose della cavità nasale metastatica
- Carcinoma a cellule squamose nasofaringeo metastatico
- Carcinoma a cellule squamose faringeo metastatico
- Carcinoma a cellule squamose sinonasali metastatico
- Carcinoma a cellule squamose ricorrente del labbro e della cavità orale
- Carcinoma a cellule squamose rinofaringeo ricorrente
- Carcinoma a cellule squamose faringeo ricorrente
- Carcinoma a cellule squamose sinonasali ricorrente
- Carcinoma rinofaringeo stadio IV AJCC v8
- Stadio IV cancro sinonasale AJCC v8
- Stage IV Testa e collo Carcinoma a cellule squamose cutanee AJCC V8
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To evaluate progression-free survival (PFS) of patients treated with chemotherapy plus cetuximab, chemotherapy plus bevacizumab, and atezolizumab plus bevacizumab. (Phase II) II. To evaluate the overall survival (OS) of patients treated with chemotherapy plus cetuximab to the superior arm from the phase II portion of the protocol. (Phase III)
SECONDARY OBJECTIVES:
I. To evaluate the OS for the subset of patients with high PD-L1 expression, defined as combined positive score (CPS) >= 20% on all arms of treatment.
II. To evaluate the toxicity of each arm of treatment.
IMAGING OBJECTIVES:
I. To establish the correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers (maximum standard uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) and expression of PD-L1 expression (Low versus high, defined as CPS < 20 versus CPS >= 20).
II. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post the initiation of treatment, PFS, and OS.
EXPLORATORY OBJECTIVE:
I. To establish the correlation between 18F-FDG PET and CT neck radiomics features and PD-L1 expressions (Low versus high - defined as CPS < 20 versus CPS >= 20).
OUTLINE: This is a randomized phase II trial followed by a randomized phase III trial.
PHASE II: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive cetuximab intravenously (IV) over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or magnetic resonance imaging (MRI) throughout the trial. Patients may undergo echocardiography (ECHO) during screening.
ARM B: Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM C: Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
PHASE III: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM B: Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
Patients undergo blood sample collection throughout the study.
After completion of study treatment, patients are followed up at 30 days and then every 3 months if patient is < 2 years from randomization and every 6 months if patient is 2-5 years from randomization.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Dublin, California, Stati Uniti, 94568
- Epic Care-Dublin
-
Emeryville, California, Stati Uniti, 94608
- Epic Care Partners in Cancer Care
-
Irvine, California, Stati Uniti, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Martinez, California, Stati Uniti, 94553-3156
- Contra Costa Regional Medical Center
-
Orange, California, Stati Uniti, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Stati Uniti, 94304
- VA Palo Alto Health Care System
-
Palo Alto, California, Stati Uniti, 94304
- Stanford Cancer Institute Palo Alto
-
-
Connecticut
-
Derby, Connecticut, Stati Uniti, 06418
- Smilow Cancer Hospital-Derby Care Center
-
Fairfield, Connecticut, Stati Uniti, 06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Glastonbury, Connecticut, Stati Uniti, 06033
- Smilow Cancer Hospital Care Center at Glastonbury
-
Greenwich, Connecticut, Stati Uniti, 06830
- Smilow Cancer Hospital Care Center at Greenwich
-
Guilford, Connecticut, Stati Uniti, 06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford, Connecticut, Stati Uniti, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven, Connecticut, Stati Uniti, 06520
- Yale University
-
North Haven, Connecticut, Stati Uniti, 06473
- Yale-New Haven Hospital North Haven Medical Center
-
Orange, Connecticut, Stati Uniti, 06477
- Smilow Cancer Hospital-Orange Care Center
-
Stamford, Connecticut, Stati Uniti, 06902
- Smilow Cancer Hospital Care Center at Long Ridge
-
Torrington, Connecticut, Stati Uniti, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Stati Uniti, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury, Connecticut, Stati Uniti, 06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford, Connecticut, Stati Uniti, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark, Delaware, Stati Uniti, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Stati Uniti, 19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Coral Gables, Florida, Stati Uniti, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Stati Uniti, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Fort Lauderdale, Florida, Stati Uniti, 33316
- Broward Health Medical Center
-
Miami, Florida, Stati Uniti, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Stati Uniti, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Stati Uniti, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Stati Uniti, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Stati Uniti, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Stati Uniti, 96817
- Queen's Cancer Center - Kuakini
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Hawaii Cancer Care - Westridge
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene, Idaho, Stati Uniti, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Stati Uniti, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stati Uniti, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Stati Uniti, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Stati Uniti, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Stati Uniti, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora, Illinois, Stati Uniti, 60504
- Rush-Copley Medical Center
-
Centralia, Illinois, Stati Uniti, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- John H Stroger Jr Hospital of Cook County
-
Danville, Illinois, Stati Uniti, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Stati Uniti, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stati Uniti, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Stati Uniti, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stati Uniti, 62401
- Carle Physician Group-Effingham
-
Harvey, Illinois, Stati Uniti, 60426
- Ingalls Memorial Hospital
-
Mattoon, Illinois, Stati Uniti, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Stati Uniti, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Stati Uniti, 62269
- Cancer Care Center of O'Fallon
-
O'Fallon, Illinois, Stati Uniti, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Stati Uniti, 60462
- University of Chicago Medicine-Orland Park
-
Springfield, Illinois, Stati Uniti, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stati Uniti, 62702
- Springfield Clinic
-
Springfield, Illinois, Stati Uniti, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center
-
Yorkville, Illinois, Stati Uniti, 60560
- Rush-Copley Healthcare Center
-
-
Iowa
-
Ames, Iowa, Stati Uniti, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Stati Uniti, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Stati Uniti, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Boone, Iowa, Stati Uniti, 50036
- McFarland Clinic - Boone
-
Clive, Iowa, Stati Uniti, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stati Uniti, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Stati Uniti, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Stati Uniti, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stati Uniti, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stati Uniti, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stati Uniti, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Stati Uniti, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Stati Uniti, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Stati Uniti, 50158
- McFarland Clinic - Marshalltown
-
Waukee, Iowa, Stati Uniti, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Stati Uniti, 50266
- Mercy Medical Center-West Lakes
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70112
- University Medical Center New Orleans
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Stati Uniti, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Stati Uniti, 21201
- University of Maryland/Greenebaum Cancer Center
-
Cumberland, Maryland, Stati Uniti, 21502
- UPMC Western Maryland
-
-
Massachusetts
-
Worcester, Massachusetts, Stati Uniti, 01655
- UMass Memorial Medical Center - University Campus
-
-
Minnesota
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Mercy Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Abbott-Northwestern Hospital
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Stati Uniti, 63703
- Saint Francis Medical Center
-
St Louis, Missouri, Stati Uniti, 63128
- Mercy Hospital South
-
-
Montana
-
Anaconda, Montana, Stati Uniti, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Stati Uniti, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stati Uniti, 59405
- Benefis Sletten Cancer Institute
-
Missoula, Montana, Stati Uniti, 59804
- Community Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- University of New Mexico Cancer Center
-
Las Cruces, New Mexico, Stati Uniti, 88011
- Memorial Medical Center-Las Cruces
-
-
North Carolina
-
Clinton, North Carolina, Stati Uniti, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Stati Uniti, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville, North Carolina, Stati Uniti, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
-
Ohio
-
Centerville, Ohio, Stati Uniti, 45459
- Miami Valley Hospital South
-
Dayton, Ohio, Stati Uniti, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Stati Uniti, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Stati Uniti, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Stati Uniti, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Stati Uniti, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Stati Uniti, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Stati Uniti, 45429
- Kettering Medical Center
-
Steubenville, Ohio, Stati Uniti, 43952
- Trinity's Tony Teramana Cancer Center
-
Toledo, Ohio, Stati Uniti, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Stati Uniti, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Stati Uniti, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Stati Uniti, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Stati Uniti, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stati Uniti, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, Stati Uniti, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, Stati Uniti, 15009
- UPMC-Heritage Valley Health System Beaver
-
Butler, Pennsylvania, Stati Uniti, 16001
- UPMC Hillman Cancer Center at Butler Health System
-
Camp Hill, Pennsylvania, Stati Uniti, 17011
- UPMC Camp Hill
-
Carlisle, Pennsylvania, Stati Uniti, 17015
- Carlisle Regional Cancer Center
-
Cranberry Township, Pennsylvania, Stati Uniti, 16066
- UPMC Hillman Cancer Center - Passavant - Cranberry
-
Erie, Pennsylvania, Stati Uniti, 16505
- UPMC Hillman Cancer Center Erie
-
Farrell, Pennsylvania, Stati Uniti, 16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg, Pennsylvania, Stati Uniti, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Greenville, Pennsylvania, Stati Uniti, 16125
- UPMC Hillman Cancer Center in Greenville/UPMC Horizon
-
Harrisburg, Pennsylvania, Stati Uniti, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Indiana, Pennsylvania, Stati Uniti, 15701
- IRMC Cancer Center
-
Johnstown, Pennsylvania, Stati Uniti, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
McKeesport, Pennsylvania, Stati Uniti, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Mechanicsburg, Pennsylvania, Stati Uniti, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, Stati Uniti, 15146
- Forbes Hospital
-
Monroeville, Pennsylvania, Stati Uniti, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Moon Township, Pennsylvania, Stati Uniti, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
Mount Pleasant, Pennsylvania, Stati Uniti, 15666
- UPMC Hillman Cancer Center - Part of Frick Hospital
-
N. Huntingdon, Pennsylvania, Stati Uniti, 15642
- Arnold Palmer Cancer Center Medical Oncology Norwin
-
Natrona Heights, Pennsylvania, Stati Uniti, 15065
- UPMC Cancer Center-Natrona Heights
-
New Castle, Pennsylvania, Stati Uniti, 16105
- UPMC Hillman Cancer Center - New Castle
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Stati Uniti, 19114
- Jefferson Torresdale Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Stati Uniti, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, Stati Uniti, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Pittsburgh, Pennsylvania, Stati Uniti, 15219
- UPMC-Mercy Hospital
-
Seneca, Pennsylvania, Stati Uniti, 16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown, Pennsylvania, Stati Uniti, 15401
- UPMC Cancer Center-Uniontown
-
Washington, Pennsylvania, Stati Uniti, 15301
- UPMC Cancer Center-Washington
-
West Mifflin, Pennsylvania, Stati Uniti, 15122
- UPMC West Mifflin-Cancer Center Jefferson
-
Williamsport, Pennsylvania, Stati Uniti, 17754
- Divine Providence Hospital
-
Willow Grove, Pennsylvania, Stati Uniti, 19090
- Asplundh Cancer Pavilion
-
York, Pennsylvania, Stati Uniti, 17408
- UPMC Memorial
-
-
Rhode Island
-
Westerly, Rhode Island, Stati Uniti, 02891
- Smilow Cancer Hospital Care Center - Westerly
-
-
South Dakota
-
Rapid City, South Dakota, Stati Uniti, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37916
- Covenant Health Cancer Centers
-
Knoxville, Tennessee, Stati Uniti, 37932
- Covenant Health Cancer Centers - West
-
Lenoir City, Tennessee, Stati Uniti, 37772
- Covenant Health Oncology Group - Lenoir City
-
Nashville, Tennessee, Stati Uniti, 37232
- Vanderbilt University/Ingram Cancer Center
-
Oak Ridge, Tennessee, Stati Uniti, 37830
- Covenant Health Oncology Group - Oak Ridge
-
-
Vermont
-
Saint Johnsbury, Vermont, Stati Uniti, 05819
- Dartmouth Cancer Center - North
-
-
West Virginia
-
Charleston, West Virginia, Stati Uniti, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Mukwonago, Wisconsin, Stati Uniti, 53149
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Stati Uniti, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Waukesha, Wisconsin, Stati Uniti, 53188
- UW Cancer Center at ProHealth Care
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Patient must have histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) (excluding squamous cell carcinoma [SCC] of salivary glands, Epstein-Barr virus [EBV]-associated nasopharynx and skin)
-
Patient must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Measurements must be obtained within 4 weeks prior to randomization
-
Patient must be >= 18 years of age
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Patient must have disease progression after prior therapy with an immune checkpoint inhibitor (ICI) in the first-line setting for recurrent/metastatic disease. Patient must have received first-line immune checkpoint inhibition for at least 6 weeks. Patients who have recurred or progressed within 12 weeks of immune checkpoint inhibition administered in the definitive setting for locally advanced disease (for e.g., in the context of a clinical trial) will also be eligible if local therapies are not feasible
-
Prior combination immunotherapies are permitted, but patient must not have had prior antiangiogenic treatment (e.g., bevacizumab, ziv-aflibercept, ramucirumab, sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, etc.). Patient must have completed any prior investigational therapy at least 28 days prior to randomization.
- NOTE: Patients who received platinum/taxanes in the locally-advanced or recurrent/metastatic setting and did not progress for at least 4 months thereafter, will be eligible for this study. Patients who received cetuximab in the locally-advanced setting and did not progress for at least 4 months thereafter, will also be eligible for this study
-
Patient must not have a history of >= grade 3 immune-related adverse event on prior ICI therapy (except those that could be managed with steroids [e.g., dermatologic toxicity, asymptomatic elevation of pancreatic enzymes, etc.]) and ICI could eventually be resumed. Patients who developed grade 3 endocrinopathies but are now stable on hormone supplementation and/or a daily prednisone dose of =< 10 mg (or equivalent doses of another glucocorticoid), will be permitted on this trial
-
Patient must not have a history of PD-1 inhibitor-induced hyper-progression, defined as 100% increase in tumor burden within 8 weeks (or 50% within 4 weeks) of initiating ICI and associated with clinical deterioration
-
Patient must not have any of the following criteria due to the possibility of increased risk for tumor bleeding with bevacizumab therapy:
- Prior carotid bleeding,
- Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by imaging studies,
- Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as shown unequivocally by imaging studies,
- Any prior history of bleeding related to the current head and neck cancer,
- History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode of coughing) within 3 months prior to randomization
-
Patient must not have uncontrolled hypertension, a history of hypertensive crisis or hypertensive encephalopathy, or a history of grade 4 thromboembolism
-
Patient must not have a history of coagulopathy or hemorrhagic disorders
-
Patient must not have a history of thrombosis (e.g., pulmonary embolism or deep venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of anticoagulation is allowed)
-
Patient must not be receiving chronic daily treatment with aspirin (> 325 mg/day) or non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function. The use of anti-platelet agents [e.g., dipyridamole (Persatine), ticlopidine (Ticlid), clopidogrel (Plavix)] is allowed only if patient is not receiving concurrent aspirin or NSAID's known to inhibit platelet function
-
Patient must have PD-L1 expression >= 1% by CPS in the tumor and/or immune cells
- NOTE: Enrolling centers should test for PD-L1 CPS preferably using the SP263 assay. Where this is not feasible, using their preferred Clinical Laboratory Improvement Act (CLIA)-certified or similar assay will be accepted. It is preferred for standard of care (SOC) PD-L1 assessments to be done on post-first line ICI samples if available, but SOC PD-L1 assessments on pre-ICI samples will be accepted for eligibility
-
Patient must not have a severe infection within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. Patients must not have active tuberculosis
-
Patient must not have a history of non-infectious pneumonitis requiring steroids at doses greater than or equal to 10 mg per day of prednisone or the equivalent on first line immunotherapy
-
Patient must not have a history of solid organ transplantation or stem-cell transplant
-
Patient must not be on immunosuppressive medication within 7 days prior to randomization except for: intranasal, inhaled, or topical steroids, local steroid injection, systemic corticosteroids at doses less than or equal to 10 mg per day of prednisone or the equivalent, or steroids used as premedication for hypersensitivity reactions
-
Patient must not have an active autoimmune disease that requires systemic treatment within 2 years prior to randomization. Patients who are receiving replacement therapy for adrenal or pituitary insufficiency will not be excluded
-
Patient must not have had a severe hypersensitivity reaction to any of the drug components used on this protocol or to chimeric or humanized antibodies or fusion proteins
-
Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study (and continue for 5 months after the last dose of atezolizumab on Arm C). Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist [registered trademark] are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
- A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of protocol treatment for patients assigned to Arms B or C.
- NOTE: Patients must also not breastfeed while on treatment and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of treatment for patients assigned to Arms B or C
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Leukocytes >= 3,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Absolute neutrophil count (ANC) >= 1,500/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Platelets >= 100,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Hemoglobin (Hgb) > 9 g/dL (must be obtained =< 14 days prior to protocol randomization) (Note: Patient may be transfused to meet this criteria)
-
Total bilirubin =< 2.0 x institutional upper limit of normal (ULN) (=< 5.0 x institutional ULN if hepatic metastases present or =< 3 x ULN for patients with known Gilbert's disease) (must be obtained =< 14 days prior to protocol randomization)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Alkaline phosphatase < 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic or bone metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Creatinine =< 1.5 x institutional ULN (must be obtained =< 14 days prior to protocol randomization)
-
Patients with uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN) must have their calcium levels corrected prior to randomization
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients must not have untreated brain metastases or leptomeningeal disease
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients must not have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients may have indwelling catheters (e.g., PleurX [registered trademark])
-
Patient must not have significant cardiovascular disease (such as New York Heart Association class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to randomization, or unstable arrhythmia or unstable angina at the time of randomization
-
Patient must not receive any other chemotherapy, immunotherapy, antitumor hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy, or experimental medications while on protocol treatment. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization and patients must be recovered from the effects of radiation (there is no required minimum recovery period
-
Patient must not have had a surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure while on protocol treatment
-
Patient must not have any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the agents used in this protocol, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
-
Patient must not have a history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo blood sample collection
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo CT scan
Altri nomi:
Undergo PET scan
Altri nomi:
Given IV
Altri nomi:
|
|
Sperimentale: Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo blood sample collection
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo CT scan
Altri nomi:
Undergo PET scan
Altri nomi:
|
|
Sperimentale: Phase II, Arm C (Bevacizumab, Atezolizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Altri nomi:
Undergo blood sample collection
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo CT scan
Altri nomi:
Undergo PET scan
Altri nomi:
Given IV
Altri nomi:
|
|
Sperimentale: Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo blood sample collection
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo CT scan
Altri nomi:
Undergo PET scan
Altri nomi:
Given IV
Altri nomi:
|
|
Sperimentale: Phase III, Arm B (Chemotherapy, Bevacizumab, Atezolizumab)
Patients receive treatment as in Arm B or C above based on results of the Phase II trial. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo CT scan
Altri nomi:
Undergo PET scan
Altri nomi:
Given IV
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Sopravvivenza libera da progressione (PFS) (Fase II)
Lasso di tempo: Tempo dall'inizio del trattamento fino alla progressione della malattia o al decesso, valutato fino a 5 anni dalla randomizzazione
|
Tempo dall'inizio del trattamento fino alla progressione della malattia o al decesso, valutato fino a 5 anni dalla randomizzazione
|
|
|
Overall survival (OS) (Phase III)
Lasso di tempo: Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Will be compared using a stratified log rank test. |
Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidenza di eventi avversi (Fase III)
Lasso di tempo: Fino a 30 giorni dopo il completamento del trattamento
|
Fino a 30 giorni dopo il completamento del trattamento
|
|
|
OS in the subset of patients with high PD-L1 expression (Phase III)
Lasso di tempo: Up to 5 years from randomization
|
The interaction of PD-L1 by treatment will also be evaluated in a Cox proportional hazards model. |
Up to 5 years from randomization
|
|
Correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers
Lasso di tempo: Up to 5 years from randomization
|
The two-sample t-test will be used to compare the difference of baseline 18F -FDG PET /CT imaging biomarkers (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) between low and high expression of PD-L1. |
Up to 5 years from randomization
|
|
Prediction of treatment response
Lasso di tempo: Baseline up to 12 weeks
|
Determined by 18FDG-PET/CT and CT neck imaging biomarkers. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post-treatment, PFS, and OS Logistic regression model will be fit to assess the association of the 18F -FDG PET /CT imaging biomarkers (e.g., SUVmax, MTV, TLG, tumor heterogeneity, tumor volume) with binary treatment response at 9-12 weeks post treatment. Cox proportional hazards models will be fit to assess the association of 18F -FDG PET /CT imaging biomarkers with time-to-event outcomes (PFS or OS). |
Baseline up to 12 weeks
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Correlation between 18F-FDG PET and CT neck radiomics features and expression of PD-L1 expression
Lasso di tempo: Up to 5 years from randomization
|
The imaging textural features from radiomics analysis will be associated with the dichotomized PD-L1 expressions. First, proper transformation will be applied to the textural features as needed to address the distribution skewness. Second, Pearson or Spearman rank correlations will be calculated between all pairs of textural features to identify highly correlated features. Third, to address overfitting and high collinearity, machine learning techniques (e.g., LASSO or XGBoost) will be employed for feature selection during the association analysis with PD-L1 expressions. |
Up to 5 years from randomization
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Aarti Bhatia, ECOG-ACRIN Cancer Research Group
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie della bocca
- Malattie stomatognatiche
- Neoplasie per sede
- Neoplasie
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie delle vie respiratorie
- Malattie otorinolaringoiatriche
- Neoplasie faringee
- Neoplasie otorinolaringoiatriche
- Malattie nasofaringee
- Malattie faringee
- Carcinoma, cellule squamose
- Malattie laringee
- Neoplasie nasofaringee
- Carcinoma rinofaringeo
- Carcinoma a cellule squamose della testa e del collo
- Carcinoma
- Neoplasie laringee
- Neoplasie della bocca
- Neoplasie orofaringee
- Neoplasie ipofaringee
- Polmonite interstiziale linfoide
- Aminoacidi, peptidi e proteine
- Proteine
- Composti di zolfo
- Prodotti chimici organici
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Complessi di coordinamento
- Taxoidi
- Ciclodecani
- Diterpenes
- Elementi
- Metalli
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Metalli, pesante
- Isotipi di immunoglobulina
- Solfuri
- Anioni
- Ioni
- Elettroliti
- Idrogeno solforato
- Composti di platino
- Elementi di transizione
- Docetaxel
- Bevacizumab
- Cetuximab
- Carboplatino
- Immunoglobulina G
- Cisplatino
- 1,2-diamminocicloesaneplatino II citrato
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Disolfuri
- Platino
- atezolizumab
- (225) AC-Dota-C (RGDYK)
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NCI-2021-10021
- U10CA180820 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2021-10021 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- EA3202 (Altro identificatore: CTEP)
- EA3202 (Altro identificatore: ECOG-ACRIN Cancer Research Group)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .